CellCarta partners with Tempus to boost oncology companion diagnostic access in the US.

CellCarta announced a strategic partnership with Tempus AI to enhance its CDx Commercialization Lab Network, focusing on oncology companion diagnostics. This collaboration allows biopharma sponsors a streamlined path from diagnostic development and regulatory approval to commercial use in US oncology practices. Tempus will facilitate test ordering and result delivery through its platform, complementing CellCarta's development and testing services. This partnership strengthens CellCarta's ability to support commercial launch strategies and improve physician access to companion diagnostics in oncology.